Aims: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL-1501D and reference insulin glargine (Lantus ® ; Sanofi-Aventis US LLC, Bridgewater, New Jersey).
nephropathy and neuropathy, and may reduce the risk of cardiovascular disease. 3, 4 Insulin is the primary therapy for individuals with T1DM, and most receive multiple daily insulin injections (basal-bolus regimens) or continuous insulin infusion. 2 Insulin glargine (Lantus ® ;
Sanofi-Aventis US LLC, Bridgewater, New Jersey), a long-acting human insulin analogue, allows once-daily basal use in people with T1DM. 5 Biologics such as insulin analogues are costly, limiting global access. 6, 7 Biosimilars, also known as follow-on biologics (FOBs) in the United States, are associated with cost savings and may help improve access to treatment. 8 Both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have provided guidelines for the development of biosimilars and FOBs, indicating that a biosimilar should be highly similar to the biologic reference product, with no clinically meaningful differences between the biosimilar and reference product in terms of safety, purity and potency. 9, 10 Non-inferiority to a licensed reference product is necessary for obtaining EMA 9 or FDA 10 approval as a biosimilar or FOB insulin or insulin analogue.
MYL-1501D, which has an amino acid sequence identical to that of reference insulin glargine, 11 has recently been approved by the EMA 12 as a biosimilar and is being developed as an FOB to insulin glargine in the United States. Determination of biosimilarity was based in part on the results of two phase 3 studies, INSTRIDE 1 and INSTRIDE 2, which demonstrated similar safety and efficacy of MYL-1501D and reference insulin glargine in patients with T1DM and type 2 diabetes mellitus, respectively (ClinicalTrials.gov identifiers: NCT02227862 and NCT02227875, respectively). 13, 14 The primary objective of the INSTRIDE 3 study was to assess whether patients with T1DM can switch between MYL-1501D and reference insulin glargine through testing equivalence after 36 weeks between two treatment sequences (ie, patients who remain on reference insulin glargine vs. those who switch between MYL-1501D and reference insulin glargine).
| MATERIALS AND METHODS

| Study design
This was a multicentre, open-label, randomized, parallel-group, phase 3 study comparing the efficacy and safety of MYL-1501D with those of US-sourced reference insulin glargine (Lantus) in patients with T1DM (ClinicalTrials.gov identifier: NCT02666430). Individuals who successfully completed 52 weeks of reference insulin glargine treatment in the INSTRIDE 1 study (NCT02227862) 13 and provided written informed consent were eligible. Individuals were excluded if they had a history of clinically significant infections, had moderate insulin resistance (requiring basal plus prandial insulin of ≥1.5 U/kg/d), or planned to receive elective surgery requiring hospitalization or another investigational drug during the study period.
Participants were randomized in a 1:1 ratio to one of two treatment sequences. The reference insulin glargine sequence group continued reference insulin glargine for 36 weeks. The MYL-1501D (treatment-switching) sequence group received MYL-1501D for weeks 0 to 12, reference insulin glargine for weeks 12 to 24, and MYL-1501D for weeks 24 to 36 ( Figure S1 ). After week 36, all participants resumed their baseline treatment and had a safety follow-up visit at week 40. Both treatments were administered as subcutaneous injections via prefilled disposable pens, with initial study doses of MYL-1501D and reference insulin glargine administered at a dose adapted to the actual blood glucose levels of the participants.
Participants also received disposable pens for subcutaneous injection of insulin lispro (Humalog ® ; Eli Lilly and Company, Indianapolis, Indiana) at mealtimes. During the study, including across treatment periods, titration of both MYL-1501D and reference insulin glargine was minimized but allowed for safety concerns (ie, if required, doses were titrated to ensure good diabetes control). Use of other antidiabetic medications was prohibited during the study period.
The primary endpoint used to demonstrate equivalence between the two treatment sequences was change in HbA1c from baseline to week 36. Secondary endpoints included change from baseline in fasting plasma glucose (FPG), eight-point self-monitored blood glucose (SMBG) profile and insulin dose per unit body weight, and immunogenicity at week 36, in addition to occurrence of hypoglycaemic events (30-day rate), nocturnal hypoglycaemic events, and adverse events (AEs). Two conventional radioimmunoprecipitation assays were used for the assessment of antidrug antibodies-one that detects antidrug antibodies against MYL-1501D and one that detects antidrug antibodies against reference insulin glargine-and the proportion of participants with a treatment-emergent antibody response (TEAR) was determined. TEAR measured whether a participant's antidrug antibody status changed during the study, identifying a relative increase in binding higher than that expected from analytical and biological variability alone. For participants without detectable antibodies at baseline, TEAR was defined as a change to a detected insulin antibody binding level of at least 1.00% or 1.15% post-baseline for the reference insulin glargine and MYL-1501D assays, respectively; for participants with detectable antibodies at baseline, TEAR was defined as a ≥ 30% relative increase in insulin antibody binding from baseline for both assays. Hypoglycaemic event rate per participant per 30 days calculated between two visits was defined as the total number of episodes between two visits divided by the number of days between the visits, multiplied by 30 days.
The study was conducted in accordance with the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects, the International Council for Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, and with applicable local regulatory requirements and laws.
The protocol was reviewed and approved by independent ethics committees/institutional review boards in accordance with local legal regulations. All participants provided written informed consent before study enrolment.
| Statistical analysis
The primary endpoint analysis was performed using the modified intention-to-treat population (mITT; all randomized participants who had at least one baseline and one post-baseline HbA1c value between weeks 24 and 36). Analysis of covariance was used to produce a 95% confidence interval (CI) for the difference between the two treatment sequence groups for the mean change from baseline in HbA1c. Equivalence of MYL-1501D to reference insulin glargine was established if the 95% CIs were within ±0.4% equivalence limits. Secondary endpoint analyses were performed using the intention-to-treat population, which included all randomized participants who had a baseline visit and at least one post-baseline visit. Treatment sequence group comparisons for secondary efficacy analysis were performed using a mixed-effects model approach. Safety analyses included participants who were randomized and took at least one dose of study drug. The hypoglycaemic event rate was analysed using a similar mixed-effects model method for treatment comparisons. For categorical data, treatment comparisons were performed using Fisher's exact or the chisquared test.
| RESULTS
| Participant disposition and baseline characteristics
Overall, 127 participants were randomized: 64 to the MYL-1501D treatment sequence group and 63 to the reference insulin glargine treatment sequence group. A total of 119 participants (93.7%) completed the study. The discontinuation rate for the total study population was 6.3% (8/127), with similar rates in the MYL-1501D and reference insulin glargine sequence groups (4.7% vs 7.9%, respectively; P = 0.49). The most common reason for study discontinuation was withdrawal of consent (5/8, 62.5%), followed by loss to follow-up (2/8, 25.0%) and AEs (1/8, 12.5%).
Baseline participant characteristics were similar between the treatment sequence groups ( Table 1 ). The majority of participants were men (n = 77, 60.6%) and white (n = 120, 94.5%), and their mean age was 44.0 years. Across both treatment sequences, the mean (SD) baseline body mass index was 26.9 
| Efficacy
The least squares (LS) mean (SE) change in HbA1c from baseline to week 36 was −0.05 (0.032) for the MYL-1501D sequence group and −0.06 (0.034) for the reference insulin glargine sequence group, with an LS mean difference of 0.01 (95% CI −0.085 to 0.101; Figure 1A ).
The study met its primary objective by demonstrating that the change in HbA1c from baseline to week 36 in the MYL-1501D treatment sequence was equivalent to the change in the reference insulin glargine treatment sequence, with the 95% CI within ±0.4% equivalence limits ( Figure 1B) . Throughout the study, HbA1c remained relatively stable for both treatment sequences, with no statistically significant changes from baseline (P values >0.05) or between treatment sequences at any time point throughout the three treatment periods ( Figure 1C ). In both treatment sequence groups, FPG and SMBG remained relatively stable throughout the three treatment periods, with no clinically significant changes from baseline or between treatment groups throughout the study ( Figures S2A and   S2B , respectively). For a summary of all endpoints at week 36, see Table S1 .
The mean (SD) daily basal insulin dose was slightly higher in the 
| Safety
Rates of treatment-emergent AEs (TEAEs) were similar between the MYL-1501D (41/64, 64.1%) and reference insulin glargine sequence groups (42/63, 66.7%; Table 2 ) during the 36-week treatment period. nocturnal hypoglycaemic events were comparable between the two treatment sequences, with no significant difference observed between treatment sequences at any visit ( Figure 3A,B) . The 30-day adjusted event rates for anytime and nocturnal hypoglycaemic events were also similar for both the MYL-1501D and reference insulin glargine treatment sequences (Figure 3C,D) . Although numerically there tended to be more nocturnal hypoglycaemic events in the MYL-1501D treatment sequence, there were no statistically significant differences between treatment sequences, and the trend held during treatment period 2, when participants in the MYL-1501D treatment sequence were receiving reference insulin glargine. No severe hypoglycaemic events occurred at any time point in the study.
Overall, immunogenicity profiles were comparable between the MYL-1501D and reference insulin glargine treatment sequences. The MYL-1501D and reference insulin glargine assays were highly correlated for both cross-reactive and total antibodies (both r ≥ 0.99). The TEAR rate is a relevant measure by which to assess immunogenicity, and the incidence of TEAR was 14.1% in the MYL-1501D treatment sequence and 14.3% in the reference insulin glargine treatment sequence. The differences between the two treatment sequences were not statistically significant in the reference insulin glargine assay ( Figure S3) ; similar results were observed for the MYL-1501D assay (data not shown).
| DISCUSSION
The study met its primary endpoint by demonstrating that the change from baseline to week 36 in HbA1c in participants who switched between MYL-1501D and reference insulin glargine was equivalent to that observed in participants who received reference insulin glargine for the duration of the trial, with the 95% CI within ±0.4% equivalence limits. In addition, both treatment sequences were comparable in terms of secondary endpoints, including FPG, SMBG and insulin dose.
Importantly, for the MYL-1501D sequence, there were no significant changes in efficacy variables when participants switched treatments during treatment periods 2 and 3.
The MYL-1501D and reference insulin glargine sequences had comparable total insulin doses throughout the study. However, it should be noted that, at baseline, the daily basal insulin dose was lower in the MYL-1501D treatment sequence compared with the ref- indicate that the two sequence groups in the present study had equivalent safety profiles throughout the study at the end of the treatment period, 13, 14 and switching treatments had no impact on TEAEs, hypoglycaemic events, immunogenicity profiles, or other safety variables.
Changes from baseline in terms of the incidence of TEAR were similar between the treatment-switching and reference insulin glargine treatment sequences. These results suggest that both insulin glargine preparations demonstrated similar immunogenic potential, well as changes in insulin dose and incidence and severity of hypoglycaemia. The findings from this switch study demonstrate that the safety and efficacy profiles in participants who switched between MYL-1501D and reference insulin glargine were equivalent to those in participants who received reference insulin glargine for the duration of the study and that MYL-1501D is safe and efficacious.
In conclusion, the INSTRIDE 3 study met its primary endpoint by demonstrating that the change from baseline to week 36 in HbA1c in participants switching between MYL-1501D and reference insulin glargine was statistically equivalent to that observed in participants receiving reference insulin glargine over a 36-week period. Overall, both treatment sequences were well tolerated, with no meaningful differences in immunogenicity. Together, the results of this study show that switching patients between MYL-1501D and reference insulin glargine resulted in similar efficacy and safety.
ACKNOWLEDGMENTS
Financial support for this study was provided by Mylan Inc, Canonsburg, Pennsylvania, and Biocon Ltd, Bangalore, India. Editorial assistance was provided under the direction of the authors by Elizabeth A. Harvie, PhD, ELS and Jennifer Rossi, MA, ELS, MedThink SciCom, with support from Mylan Inc.
PRIOR PRESENTATION
These data were previously presented in part at the 3rd World Congress on Clinical Trials in Diabetes, December 3-4, 2018, Vienna, Austria.
